Answers are grounded in this paper and cite their sources.
OBJECTIVES: Patients with Trisomy 21 (T21) are more susceptible to sedation-related adverse events (AEs). Few studies address the risk of propofol or compare natural airway sedation regimens in this population. Dexmedetomidine (DEX) is less likely than propofol to result in AEs as it promotes a more natural sleep and less airway muscle relaxation. METHODS: This study is a secondary analysis of prospectively collected data. We queried the Pediatric Sedation Research Consortium (PSRC) Database from the years 2020 to 2025. The demographic characteristics were summarized using descriptive statistics. The incidence of sedation-related AEs and sedation failures were described by induction drug (DEX vs. propofol). Any medication used other than DEX or propofol were excluded. We performed a propensity score analysis comparing the DEX cohort to the propofol cohort. All the statistical work was performed using SAS 9.4. RESULTS: A total of 337 patients met inclusion criteria. The average age was 7 years. Forty-four percent of AEs were partial airway obstruction. For the bivariate analyses, the AE outcome variable is statistically significant with the medication variable (χ2df=1=33.249, P<0.001). Induction with propofol had a 5 times higher odds of an AE (OR=5.069, 95% CI: 2.829-9.082). After propensity score matching, there are a total of 216 matched observations. CONCLUSION: In patients with T21 undergoing radiologic procedures, the odds of having any AE are higher with induction using propofol compared with DEX. Greater consideration should be given for use of DEX induction for patients with T21 undergoing sedated radiologic procedures.
No takes yet. Share an insight, caveat, or question.
Sulton et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: